Discover details of Bristol-Myer Squibbs latest immuno-oncology drug deal, DiaCarta’s funding into its diagnostic platform and Cancer Research UK’s pledge to invest £45 million into clinical trials.
Browsing: Taxonomy > Clinical trials
Delve deeper into the promising PD-L1 research being published, in this patient perspective piece from Stage IV melanoma patient T.J. Sharpe.
Data from the CheckMate-227 trial has demonstrated that its cancer drug combination has reached its primary endpoint of progression-free survival.
From clinical trial results to major drug approvals, here we present an overview of the latest industry news from the biggest players in oncology.
Merck has extended its all-important lung-cancer lead, after combination Phase III trial demonstrates that Keytruda extends lung cancer survival.
A phase III trial examining the use of cabozantinib for patients with previously treated advanced hepatocellular carcinoma has met its primary endpoint of overall survival.
Researchers have presented the association between tumor response and health-related quality of life in patients with metastatic Merkel cell carcinoma treated with avelumab.
Researchers have demonstrated that breast cancer can resurface 15 years after treatment, epigenetic editing has revealed a surprising insight into early breast cancer development and two breakthrough CDK4/6-inhibitor drugs have been approved for advanced breast cancer.
Find out about IMPACT, a partnership between Anthony Nolan, Leuka, NHS Blood and Transplant and the University of Birmingham (UK), which aims to deliver the UK’s first large-scale clinical trials program in this exclusive blog piece.
In this interview with the Vice President of Global Development at Amgen we take a more in-depth look at the trastuzumab data, an oncology biosimilar medicine.